Linden Capital Partners, a Chicago-based private equity firm focused on the healthcare and life science industries, has brought aboard Chris Kolber as an operating partner. Kolber was previously the president of global devices at Hospira and division vice president of licensing and new business development at Abbott Laboratories, where he spent 25 years in various roles.
Linden Capital Partners, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare sector, today announced the addition of Chris M. Kolber as an operating partner.
Mr. Kolber was a member of the Hospira executive team in the 2004 spin out from Abbott Laboratories and recently served as president, Global Devices, a $1 billion segment of Hospira’s business. He is a 30-year veteran of the healthcare industry with extensive experience in the medical products and specialty and generic pharmaceutical sectors. Prior to Hospira, Mr. Kolber spent 25 years at Abbott Laboratories in various general management and corporate development roles including division vice president of licensing and new business development. Mr. Kolber began his career in the Hospital Products division of Abbott and was instrumental in the development of Abbott’s Drug and Drug Delivery Systems business.
Mr. Kolber augments Linden’s group of operating partners who collectively have more than a century of healthcare experience. He will work closely with Linden’s investment team to source and perform due diligence on new opportunities as well as to support existing portfolio companies.
About Linden Capital Partners ( www.lindenllc.com )
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s investment strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently manages $575 million in capital.